Asciminib Hydrochloride

CHEMBL4297220 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

486.3 g/mol

LogP

—

Phase

4

The hydrochloride salt of asciminib that blocks the BCR-ABL1 oncoprotein through a novel allosteric mechanism, offering an option for patients with CML whose leukemia has resisted other tyrosine kinase inhibitors.

Peso Molecular

486,3000 g/mol

TPSA

103,00 Å²

Mecanismo de Ação

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1

InChI

InChI=1S/C20H18ClF2N5O3.ClH/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28;/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30);1H/t14-;/m1./s1

Molecular Formula

C20H19Cl2F2N5O3

HBD / HBA

4 / 8

Ligações Rotacionáveis

6

Átomos Pesados

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The hydrochloride salt of asciminib that blocks the BCR-ABL1 oncoprotein through a novel allosteric mechanism, offering an option for patients with CML whose leukemia has resisted other tyrosine kinase inhibitors.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Asciminib Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297220. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 133082086. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Asciminib Hydrochloride no PillFYI

Estrutura

Dados Rápidos

Fórmula: C20H19Cl2F2N5O3

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.